Gan & Lee Pharmaceuticals Co., Ltd. Class A

Gan & Lee Pharmaceuticals Co., Ltd. Class A

SSSE:603087
63.51
CNY
-0.59
(-0.92%)
2.01EPS
38.58P/E
46.24BMarket Cap
Apr 29Next Earn
Gan & Lee Pharmaceuticals Co., Ltd. Class A
SSE:603087
(Shanghai Stock Exchange)

Recent

price

63.51

P/E

ratio

38.58

div

yld

0.00%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.47
1.84
2.41
3.5
4.69
4.73
5.73
6.31
6.44
3.04
4.6
5.15
6.84
7.42
Revenue per Share
0.44
0.61
0.89
1.52
2.14
1.85
2.31
2.31
2.59
-0.78
0.6
1.04
1.93
2.01
Basic EPS, GAAP
- -
- -
- -
- -
1.03
-0.19
1.49
1.24
0.69
-1.22
-0.78
0.16
-0.24
- -
Free Cash Flow per Basic Share
0.06
- -
0.01
- -
- -
- -
- -
0.38
0.4
0.3
- -
0.71
1.01
- -
Dividend per Share
1.56
2.21
3.17
4.81
6.6
8.52
10.83
15.92
18.11
16.95
18.08
18.39
19.47
20.05
Book Value per Share
1.21
1.85
2.81
4.45
6.18
7.68
9.66
14.55
16.55
15.13
16.24
16.41
16.33
16.05
Tangible Book Value per Share
470
503
505
506
506
505
505
533
561
563
567
591
593
590
Basic Weighted Avg Shares
693
927
1,220
1,771
2,371
2,387
2,895
3,362
3,612
1,712
2,608
3,045
4,052
4,374
Sales/Revenue/Turnover
33.42
36.72
42.57
50.47
53.25
46.86
46.27
42.53
40.41
-32.95
9.46
10.21
19.59
22.26
Operating Margin (%)
- -
- -
- -
- -
51
91
116
160
185
200
225
257
303
- -
Depreciation Expense
205
305
447
770
1,080
934
1,167
1,231
1,453
-440
340
615
1,144
1,183
Net Income, GAAP
15.21
14.12
14.9
15.13
14.83
16.13
16.47
14.86
14.34
- -
- -
2.49
7.01
7.61
Effective Tax Rate (%)
29.56
32.94
36.68
43.45
45.56
39.12
40.32
36.61
40.22
-25.67
13.04
20.18
28.22
27.05
Profit Margin (%)
444
452
660
1,043
1,634
2,127
2,652
5,546
6,385
4,851
5,402
2,990
4,668
5,467
Working Capital
- -
- -
61
3
- -
- -
1
16
12
8
5
3
3
230
LT Debt
733
1,038
1,486
2,256
3,335
4,303
5,471
8,938
10,167
9,586
10,743
11,054
11,628
11,977
Total Equity
- -
32.35
33.05
38.58
37.5
23.91
23.2
16.84
15.06
- -
- -
5.65
9.67
10.29
Return on Invested Capital (%)
- -
34.1
34.34
39.83
38.22
24.25
23.7
17
15.18
- -
- -
5.64
10.07
10.21
Return on Capital (%)
- -
34.46
35.45
41.14
38.63
24.45
23.89
17.08
15.21
-4.45
3.35
5.64
10.08
10.32
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8
8
5
LT Borrowings
- -
- -
228
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
597
597
597
Market Capitalization
38,228
33,903
46,241

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,403
5,896
6,711
Cash, Cash Equivalents & STI
3,416
3,520
4,259
Accounts Receivable, Net
408
758
884
Inventories
1,090
1,056
1,192
Total Current Liabilities
677
853
1,244
Payables & Accruals
- -
- -
- -
ST Debt
8
8
5
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.74%
5.64%
5.19%
Free Cash Flow
- -
-144.68%
-246.94%
Net Income, GAAP
0.64%
-24.56%
86.05%
Sales/Revenue/Turnover
17.41%
11.4%
33.06%
Total Cash Common Dividend
- -
- -
42.08%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
560
755
930
800
3,045
2025
985
1,082
- -
1,005
4,052
2026
878
1,345
1,146
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.34
0.35
0.18
1.04
2025
0.53
0.49
- -
0.55
1.93
2026
0.33
0.7
0.42
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.03
0.51
0.71
2025
- -
- -
- -
- -
1.01
2026
- -
- -
- -
- -
- -
Business
Gan & Lee Pharmaceuticals Co Ltd (603087.SS) is a biopharmaceutical company specializing in the research, development, production and commercialization of insulin analogs, active pharmaceutical ingredients and related medical devices for diabetes management. The company offers a portfolio of recombinant insulin products including Basalin (insulin glargine injection), Prandilin (insulin lispro injection), Prandilin 25 (insulin lispro mix 75/25), Rapilin (insulin aspart injection), Rapilin 30 (insulin aspart 30) and Similin 30 (insulin injection); insulin delivery devices such as GanleePen (insulin injection pen) and GanleeFine (insulin pen needle). Founded in 1998 and headquartered at No. 8 Nanfeng West 1st Street, Huoxian, Tongzhou District, Beijing, China, Gan & Lee operates primarily in the diabetes therapeutics segment with products registered in 23 countries, launched in 19 and under clinical trials in 10, targeting patients with type 1 and type 2 diabetes across China and international markets including Brazil, the US and Europe. In recent developments, Gan & Lee signed a national Technology Transfer and Supply Agreement with Brazil's Fiocruz public laboratory, witnessed by the Brazilian Ministry of Health, to localize insulin manufacturing and accelerate market access; the company also entered a License and Supply Agreement with PC for the global rollout of its biweekly GLP-1 receptor agonist Bofanglutide (GZR18) in Latin America. Further advancing its pipeline, Gan & Lee initiated the US Phase 2 clinical trial of Bofanglutide (GZR18) injection for overweight or obesity patients following FDA IND clearance and dosed the first participant in Phase 3 GRADUAL-3 study in China; the US FDA accepted Biologics License Applications for insulin glargine, lispro and aspart injections, while GanleeFine pen needles received EMA GMP approval in 2024. The company ranked first in procurement demand for insulin analogs in China's 2024 National Insulin-Specific Centralized Procurement and appointed Dr. Ting JIA as Corporate Vice President and Chief Medical Officer to support global expansion of innovative drugs. Gan & Lee maintains GMP-compliant facilities including its Beijing recombinant human insulin production base and the under-construction Linyi Production Base, pursuing a dual strategy of innovation and globalization in metabolic diseases.